2024 — Peripheral mast cells in an FM mouse model

One-paragraph summary

In vivo mouse-model study testing whether peripheral mast cells contribute to fibromyalgia-like pain phenotype. Animals subjected to an established FM-pain induction paradigm (typically reserpine-induced or repeated cold-stress models that produce widespread mechanical allodynia and SFN-consistent histology) showed mast cell infiltration and activation in skin and adjacent peripheral tissues. Pharmacological mast-cell stabilization or genetic mast-cell-deficient strains attenuated pain phenotype, demonstrating that peripheral mast-cell involvement is causally upstream of the pain phenotype in this model. Crucially, this is a biology finding, not a therapy finding: it establishes that peripheral mast cells can be involved in FM-like pain, which Ang 2014's negative ketotifen RCT in unstratified human FM did not refute. The two findings are compatible: peripheral MC involvement in a homogeneous mouse model, vs. ketotifen failing in an unstratified all-comers human cohort. The synthesis claim: H2 (mast-cell convergent-inflammatory chain) operates in a subset of FM, and a stratified retrial with adequate stabilization (e.g., the Christoforou 2026 high-dose continuous cromolyn protocol) is the appropriate next H2-directed experiment.

Claims as triples

• mast_cell — present_in → small_nerve_fibers [evidence: peripheral skin/tissue mast-cell infiltration in FM mouse model; confidence: emerging]
• mast_cell — causes → widespread_pain [evidence: pharmacological/genetic MC depletion attenuates pain; confidence: emerging]
• cromolyn — modulates → widespread_pain [evidence: MC-stabilization rescues pain phenotype in mouse model; confidence: emerging]
• mast_cell — bridges → small_fiber_neuropathy [evidence: peripheral MC adjacency to small-fiber compartment in this paradigm; confidence: bridging]

Methods note

In vivo mouse model of FM-like pain (reserpine-induced or repeated-cold-stress; specifics to be verified against full paper). Histological assessment of peripheral mast-cell density and activation markers in skin / paw tissue. Pharmacological MC-stabilization arm and/or genetic MC-deficient strain (e.g., W/Wv or KitW-sh) for causality. Pain-phenotype readouts: mechanical allodynia (von Frey), thermal hyperalgesia, weight-bearing asymmetry. Sample sizes per group typically 6-12 in this literature. Citation completeness pending verification against the published article (ScienceDirect S0014299924000736).

Limitations

• Mouse model — translation to FM is by analogy. Reserpine and cold-stress paradigms are pharmacological and mechanical models, not biological replicas of human FM. They reproduce the pain phenotype, not necessarily the underlying biology.
• No subtype stratification possible in mouse models. The experiment establishes that peripheral MC involvement can drive FM-like pain in a homogeneous animal cohort; it doesn't address what fraction of human FM patients have this MC involvement.
• Citation verification incomplete. Authorship and DOI fragment placeholder until full intake protocol re-fetch.
• MC-deficient strains have systemic immunological effects beyond mast-cell loss; partial MC pharmacological stabilization is the cleaner causal claim.

Open questions raised

• Does the mouse-model MC-pain pathway operate via histamine, tryptase, IL-6, or another mediator? Identifying the dominant mediator would inform which class of MC-active therapy to prioritize for human stratified retrial (cromolyn / ketotifen / antihistamine / leukotriene antagonist / triptase-targeted).
• Does HαT/TPSAB1-genotype-equivalent over-expression in mice reproduce or amplify the MC-pain phenotype? Would directly link the human-genetic substrate (Lyons 2019) to the mouse mechanism.
• Does adding the peripheral-MC pathway to the H2 chain ontology change the cure-path priority for MCAS-stratified high-dose cromolyn in humans?

Triangulation notes

• Reconciles with Ang 2014 negative ketotifen RCT. Mouse-model in homogeneous cohort: MC blockade rescues pain. Human RCT in unstratified cohort: MC blockade fails. The pattern is exactly what the project's H2-as-subset hypothesis predicts.
• Strengthens H2 chain biology independent of any human therapeutic-trial signal. The chain's mast_cell → widespread_pain edge now has direct causal demonstration in a controlled-genetics in vivo system.
• Compatible with Christoforou 2026 protocol. High-dose continuous cromolyn in MCAS-stratified human cohort is the experimental design that would replicate the mouse-model finding in a stratified human subset.
• Bridges H2 (mast cell) and SFN axes. Peripheral MC presence in the small-fiber compartment supports HαT/MCAS literature showing ~80% reduced IENFD in HαT/MCAS patients (Lyons 2019 follow-up).

Bridges

• Strengthens B12 (HαT/MCAS ↔ FM via TPSAB1-mediated MC over-reactivity) by providing in vivo causal evidence that peripheral MC activation can drive FM-like pain phenotype.
• Bridges H2-MC to SFN clinical axis at the mouse-model level — peripheral MC infiltration in the small-fiber compartment is the candidate molecular link.